1h-Cyclopenta[a]phenanthren-3-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 1h-Cyclopenta[a]phenanthren-3-one
• 英文别名: 1,2-dihydrocyclopenta[a]phenanthren-3-one
• 化学式: C₁₇H₁₂O
• 分子量: 232.28
• InChiKey: CPWUCGGAHLHYTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] PROGESTERONE PHOSPHATE ANALOGS AND USES RELATED THERETO<br/>[FR] ANALOGUES DE PHOSPHATES DE PROGESTÉRONE ET UTILISATIONS ASSOCIÉES
  申请人：UNIV EMORY

  公开号：WO2015023593A1

  公开（公告）日：2015-02-19

  This disclosure relates to progesterone phophate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or stroke.

  本公开涉及孕酮磷酸盐衍生物及其相关用途。在某些实施方式中，本公开涉及本文所披露的化合物及其用于管理炎症的用途，例如由创伤性脑损伤或中风引起的炎症。
• NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION
  申请人：Sphaera Pharma Pvt. Ltd.

  公开号：EP2948152A2

  公开（公告）日：2015-12-02
• PROGESTERONE PHOSPHATE ANALOGS AND USES RELATED THERETO
  申请人：Emory University

  公开号：EP3033350A1

  公开（公告）日：2016-06-22
• NEUROSTEROID COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS
  申请人：The Texas A&M University System

  公开号：EP3784682A1

  公开（公告）日：2021-03-03
• [EN] NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION<br/>[FR] NOUVEAUX COMPOSÉS DE 11BÊTA-HYDROXY-STÉROÏDES DESTINÉS À ÊTRE UTILISÉS UTILISATION DANS LA BIOGENÈSE DE MITOCHONDRIES ET LES MALADIES ASSOCIÉES AVEC LA DYSFONCTION OU LA DÉPLÉTION MITOCHONDRIALE
  申请人：SPHAERA PHARMA PRIVATE LTD

  公开号：WO2014115167A2

  公开（公告）日：2014-07-31

  The present invention provides novel compounds of 11β-hydroxy steroids and compositions and their application as pharmaceuticals for preventing or reversing injury to mitochondria, for treating or preventing diseases relating to mitochondrial dysfunction or depletion, and for inducing regeneration or restructuring of mitochondria as a means of treating diseases relating to abnormalities in mitochondrial structure and function in a human or animal subject. Also disclosed herein are methods for diagnosing injury to mitochondria and for diagnosing the success or failure of therapeutics designed to treat, prevent, or reverse injury to or depletion of mitochondria.